Clinical trial
Study to Determine if Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine is Safe, Immunogenic and Efficacious in the Influenza Human Viral Challenge Model
NCT02522754 is registered in ClinicalTrials.gov with Hvivo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study to Determine if Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine is Safe, Immunogenic and Efficacious in the Influenza Human Viral Challenge Model
- Lead sponsor
- Hvivo
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 31, 2002
- Completion date
- January 31, 2004
- Enrollment
- 174 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
influenza